27
Participants
Start Date
September 30, 2009
Primary Completion Date
February 28, 2013
Study Completion Date
February 28, 2013
Eltrombopag
Eltrombopag starting at 25 mg dose and titrated in Part 1 of study to 50, 75, 100 mg. Platelet count must reach sufficient level to allow initiation of antiviral therapy. Eltrombopag dose may be adjusted during antiviral treatment phase of study to maintain platelet count to continue antiviral therapy without adjustment to antiviral dose.
Antiviral therapy
Combination of either peginterferon alfa-2a or alfa-2b with ribavirin at investigator's discretion.
GSK Investigational Site, Randwick
GSK Investigational Site, Camperdown
GSK Investigational Site, Herston
GSK Investigational Site, Athens
GSK Investigational Site, Berlin
GSK Investigational Site, Manhasset
GSK Investigational Site, Marseille
GSK Investigational Site, A Coruña
GSK Investigational Site, Genoa
GSK Investigational Site, Milan
GSK Investigational Site, Madrid
GSK Investigational Site, Pessac
GSK Investigational Site, Pontevedra
GSK Investigational Site, Nashville
GSK Investigational Site, Bologna
GSK Investigational Site, Düsseldorf
GSK Investigational Site, Valencia
GSK Investigational Site, Lahore
GSK Investigational Site, Freiburg im Breisgau
GSK Investigational Site, Munich
GSK Investigational Site, Ulm
GSK Investigational Site, San Diego
GSK Investigational Site, Honolulu
GSK Investigational Site, Seattle
GSK Investigational Site, New Haven
GSK Investigational Site, Toronto
GSK Investigational Site, Montreal
GSK Investigational Site, Nice
Lead Sponsor
GlaxoSmithKline
INDUSTRY